APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study
Study on the Safety and Effectiveness of APrevent® VOIS Implants for Treatment in Patients With Unilateral Vocal Fold Paralysis (UVFP) - a Two-Part, Open-Label, Non-Randomized Multicenter Study
APrevent Biotech GmbH
30 participants
Nov 13, 2019
INTERVENTIONAL
Conditions
Summary
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
Eligibility
Inclusion Criteria6
- Male and female patients between 18 and 80 years
- Diagnosed with permanent UVFP and insufficient glottal closure
- A significant voice disorder as measured by perceptual rating (Grade ≥2 GRBAS Scale) and Voice Handicap Index (VHI-30 score >33)
- Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
- Ability to co-operate with the Investigator and to comply with the requirements of the entire study
- Availability to volunteer for the entire study duration, willing to adhere to all protocol requirements and willing and able to give informed consent for participation
Exclusion Criteria16
- Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the clinical investigation may influence the result of the clinical investigation, or the participant's ability to participate in the clinical investigation
- Scheduled elective surgery or other procedures requiring general anaesthesia during clinical investigation
- Bilateral vocal fold paralysis
- Had injection medialization laryngoplasty with the injectable still being within the double length of the maximum resorption time frame as stated in their approval or as supported by literature.
- Presence of structural vocal fold lesions such as polyp or nodules
- Presence of oropharyngeal or laryngeal tumors
- Patients with diagnosed severe obstructive sleep apnea (OSA)
- Status post total cordectomy
- Previous laryngeal framework surgery (any type of thyroplasty, arytenoid adduction)
- Status post tracheostomy
- Presence of acute systemic infection at time of screening or shortly before surgery
- Significant non-laryngeal speech abnormality (severe dysarthria determined by a panel of trained speech therapists)
- Severe coagulopathy
- Females who are pregnant, lactating or planning pregnancy are excluded from the investigation
- Patients with bil. Gr. III-IV hypertrophic tonsils
- Diabetes mellitus with poor control and poor wound healing history
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05119842